End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
35.06 NZD | +2.22% | +1.07% | -1.24% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.56 times its sales, is clearly overvalued in comparison with peers.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- The company benefits from high valuations in earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.24% | 3.93B | B- | ||
+16.29% | 71.39B | C+ | ||
+1.76% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+7.95% | 8.19B | B | ||
-20.48% | 7.91B | B- | ||
+15.26% | 4.31B | B+ | ||
-3.02% | 3.86B | B | ||
+21.10% | 3.64B | C+ | ||
+7.96% | 3.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EBO Stock
- Ratings EBOS Group Limited